文献速递神经肿瘤功能神经外科

三叉神经受压肿瘤切除后面部疼痛与感觉结局

Facial pain and sensory outcomes following resection of tumors compressing the trigeminal nerve.
PubMed 文献 · J Neurosurg · 2021-10-08

多数脑膜瘤或前庭神经鞘瘤患者术后疼痛和感觉异常立即改善且持续,麻木改善较慢;肿瘤较小和三叉神经完全减压与疼痛改善相关。

要点

  • 肿瘤切除后81%患者疼痛立即改善,6周时达92%。
  • 感觉异常立即改善80%,6周时84%;麻木改善较慢,2年时79%。
  • 肿瘤直径每增大1cm,BNI疼痛评分改善的OR为0.47(95%CI 0.22-0.99;p=0.047)。

核心结论

  • 多数由脑膜瘤或前庭神经鞘瘤导致面部感觉症状的患者在切除术后症状改善。
  • 疼痛和感觉异常改善迅速且持续,麻木改善较慢。
  • 肿瘤较小和三叉神经完全减压的患者更可能获得面部疼痛改善。

研究设计与样本

  • 中位随访3.1年;63例(73%)为脑膜瘤,23例(27%)为前庭神经鞘瘤。
  • 采用逻辑回归、递归分区和时间-事件分析报告结局并识别与面部感觉结局相关的变量。

主要发现

  • 脑膜瘤患者疼痛、麻木和感觉异常的发生率分别为56%、76%和25%;前庭神经鞘瘤患者分别为9%、91%和39%。
  • 多数脑膜瘤患者症状持续时间小于1年(60%),多数前庭神经鞘瘤患者症状持续1-5年(59%)。
  • 脑膜瘤中位直径3.0 cm,前庭神经鞘瘤中位直径3.4 cm。
  • 脑膜瘤全切除、近全切除和次全切除分别占27%、29%和44%;前庭神经鞘瘤分别占9%、30%和61%。
  • 疼痛在切除后立即改善81%,6周时92%;感觉异常立即改善80%,6周时84%;麻木立即改善52%,2年时79%。

关键数值与推荐

  • 肿瘤直径显著预测BNI评分改善(OR 0.47/cm larger,95%CI 0.22-0.99;p=0.047)。
  • 三叉神经完全减压与疼痛定性改善相关(p=0.037)。
  • 三叉神经完全减压与疼痛复发减少相关(OR 0.08,95%CI 0.01-0.67;p=0.024)。

临床怎么用

  • 对因脑膜瘤或前庭神经鞘瘤导致面部感觉症状的患者,手术切除可带来疼痛和感觉异常的快速持续改善。
  • 术后麻木改善较慢,需长期随访评估。
  • 实现三叉神经完全减压可能降低疼痛复发风险。
  • 肿瘤较小者疼痛改善的可能性更高。

局限性

  • 回顾性研究设计。
  • 排除了三叉神经鞘瘤,结论不适用于该亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tumors compressing the trigeminal nerve can cause facial pain, numbness, or paresthesias. Limited data exist describing how these symptoms change after resection and what factors predict symptom improvement. The objective of this study was to report trigeminal pain and sensory outcomes after tumor resection and identify factors predicting postoperative symptom improvement. METHODS: This retrospective study included patients with tumors causing facial pain, numbness, or paresthesias who underwent resection. Trigeminal schwannomas were excluded. Logistic regression, recursive partitioning, and time-to-event analyses were used to report outcomes and identify variables associated with facial sensory outcomes. RESULTS: Eighty-six patients met inclusion criteria, and the median follow-up was 3.1 years; 63 patients (73%) had meningiomas and 23 (27%) had vestibular schwannomas (VSs). Meningioma patients presented with pain, numbness, and paresthesias in 56%, 76%, and 25% of cases, respectively, compared with 9%, 91%, and 39%, respectively, for patients with VS. Most meningioma patients had symptoms for less than 1 year (60%), whereas the majority of VS patients had symptoms for 1-5 years (59%). The median meningioma and VS diameters were 3.0 and 3.4 cm, respectively. For patients with meningiomas, gross-total resection (GTR) was achieved in 27% of patients, near-total resection (NTR) in 29%, and subtotal resection (STR) in 44%. For patients with VS, GTR was achieved in 9%, NTR in 30%, and STR in 61%. Pain improved immediately after tumor resection in 81% of patients and in 92% of patients by 6 weeks. Paresthesias improved immediately in 80% of patients, increasing to 84% by 6 weeks. Numbness improved more slowly, with 52% of patients improving immediately, increasing to 79% by 2 years. Pain recurred in 22% of patients with meningiomas and 0% of patients with VSs. After resection, the Barrow Neurological Institute (BNI) facial pain intensity score improved in 73% of patients. The tumor diameter significantly predicted improvement in BNI score (OR 0.47/cm larger, 95% CI 0.22-0.99; p = 0.047). Complete decompression of the trigeminal nerve was associated with qualitative improvement in pain (p = 0.037) and decreased pain recurrence (OR 0.08, 95% CI 0.01-0.67; p = 0.024). CONCLUSIONS: Most patients with facial sensory symptoms caused by meningiomas or VSs experienced improvement after resection. Surgery led to immediate and sustained improvement in pain and paresthesias, whereas numbness was slower to improve. Patients with smaller tumors and complete decompression of the trigeminal nerve were more likely to experience improvement in facial pain.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Castro MRH, Magill ST, Morshed RA, et al. Facial pain and sensory outcomes following resection of tumors compressing the trigeminal nerve. J Neurosurg. 2021. PMID: 34624867. doi:10.3171/2021.4.JNS203612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。